Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy PMI?
Source: PRnewswire
- Legal Claims Investigation: Faruq & Faruqi, LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Affected investors are encouraged to contact Faruq & Faruqi's Securities Litigation Partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, highlighting the importance of timely action.
- Market Impact: This investigation may negatively affect Picard Medical's stock price, prompting investors to monitor legal developments to assess the risks and potential losses associated with their investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- False Promotion Exposed: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and harming investors' interests.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the Class Period, the company failed to disclose material adverse facts regarding its business, operations, and prospects, specifically that it was affected by a fraudulent stock promotion scheme, misleading investors about its true condition.
- Investor Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in this class action lawsuit to recover losses incurred due to false information, underscoring the importance of timely legal action.
See More
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 2 and October 31, 2025, with a deadline to contact the firm by April 3, 2026.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in significant losses for investors once the truth was revealed.
- Legal Representation Information: The Schall Law Firm offers free consultations to affected investors, encouraging them to reach out before class certification to ensure their rights are protected, as failing to act may result in being an absent class member and losing the chance to claim damages.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally and emphasizing its expertise and experience in securities law to assist investors in recovering their losses.
See More
- Legal Claims Investigation: Faruq & Faruqi is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is set for April 13, 2026, urging investors to act promptly to protect their rights.
- Stock Exchange Listing: Picard Medical is listed on the New York Stock Exchange (NYSE:PMI), and this investigation may negatively impact its stock price, prompting investors to monitor developments closely to assess potential risks.
See More
- Class Action Deadline: The lead plaintiff deadline for the Picard Medical securities class action is April 13, 2026, requiring investors to apply by this date to represent other investors and protect their rights in the litigation.
- No Upfront Costs: Investors joining the class action incur no upfront fees or costs, as attorney fees will be covered through a contingency fee arrangement, reducing the financial burden on investors and encouraging broader participation from affected parties.
- False Statement Allegations: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and operations during the securities trading period, including a fraudulent stock promotion scheme involving social media, which may have led to investor losses.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, prompting investors to carefully consider the qualifications and track record of their legal counsel.
See More
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is accused of making false statements regarding a partnership with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Plug Power Lawsuit: Plug Power, Inc. faces allegations of overstating the likelihood of receiving DOE Loan funds from January 17 to November 13, 2025, which may force the company to pivot to smaller projects, with investors needing to act by April 3, 2026.
- Picard Medical Lawsuit: Picard Medical, Inc. is implicated in a fraudulent stock promotion scheme involving misinformation from September 2 to October 31, 2025, leading to artificial stock price inflation, with a lead plaintiff deadline of April 3, 2026.
- BlackRock TCP Capital Lawsuit: BlackRock TCP Capital Corp. is accused of failing to appropriately value investments from November 6, 2024, to January 23, 2026, resulting in understated losses and overstated NAV, with a lead plaintiff deadline of April 6, 2026.
See More
- Richtech Robotics Lawsuit: Richtech Robotics Inc. (NASDAQ:RR) faces a class action lawsuit for making false statements during the period from January 27 to January 29, 2026, with a lead plaintiff deadline of April 3, 2026, highlighting the urgency for affected investors to act to preserve their claims.
- Picard Medical Allegations: Picard Medical, Inc. (NYSE:PMI) is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, with a similar deadline of April 3, 2026, for investors to file as lead plaintiffs, emphasizing the potential loss of rights if they fail to act.
- Plug Power Misstatements: Plug Power, Inc. (NASDAQ:PLUG) is alleged to have overstated the availability of funds related to a DOE loan during the period from January 17 to November 13, 2025, with a lead plaintiff deadline of April 3, 2026, indicating the need for investors to protect their interests promptly.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz advise investors who have suffered losses in the aforementioned companies to contact them for legal rights discussions, stressing the importance of timely participation in class actions to safeguard their interests.
See More










